HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Open in Screener

ZBIO

Zenas Biopharma Inc

Last Close
Mar 24  •  03:54PM ET
21.22
Dollar change
+0.59
Percentage change
2.84 %
Healthcare • Biotechnology • USA • NASD
Held by: XBI VTI IWM VXF IWN IBB SCHA VTWO FFSM VFMO
IndexRUT P/E- EPS (ttm)-8.44 Insider Own56.05% Shs Outstand54.49M Perf Week-9.65%
Market Cap1.22B Forward P/E- EPS next Y-4.73 Insider Trans3.83% Shs Float25.21M Perf Month-18.84%
Enterprise Value953.69M PEG- EPS next Q-1.47 Inst Own42.77% Short Float31.83% Perf Quarter-41.31%
Income-377.74M P/S121.69 EPS this Y42.83% Inst Trans11.73% Short Ratio8.98 Perf Half Y11.95%
Sales10.00M P/B4.77 EPS next Y1.88% ROA-100.25% Short Interest8.02M Perf YTD-41.57%
Book/sh4.44 P/C3.55 EPS next 5Y23.12% ROE-136.22% 52W High44.60 -52.43% Perf Year127.87%
Cash/sh5.98 P/FCF- EPS past 3/5Y-39.47% - ROIC-117.68% 52W Low6.11 247.22% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin99.44% Volatility9.83% 7.66% Perf 5Y-
Dividend TTM- EV/Sales95.37 EPS Y/Y TTM-116.54% Oper. Margin-2113.85% ATR (14)2.00 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.61 Sales Y/Y TTM100.00% Profit Margin-3777.37% RSI (14)35.42 Recom1.25
Dividend Gr. 3/5Y- - Current Ratio5.61 EPS Q/Q-310.86% SMA20-13.24% Beta-0.78 Target Price42.00
Payout- Debt/Eq0.33 Sales Q/Q-100.00% SMA50-8.06% Rel Volume0.44 Prev Close20.63
Employees167 LT Debt/Eq0.33 EarningsMar 16 BMO SMA200-7.39% Avg Volume893.30K Price21.22
IPOSep 13, 2024 Option/ShortYes / Yes EPS/Sales Surpr.-353.37% -100.00% Trades Volume390,294 Change2.84%
Date Action Analyst Rating Change Price Target Change
Jan-05-26Downgrade Morgan Stanley Overweight → Equal-Weight $19
Mar-20-25Initiated Wedbush Outperform $35
Feb-04-25Initiated Wolfe Research Outperform $19
Dec-16-24Initiated H.C. Wainwright Buy $30
Nov-05-24Initiated Rodman & Renshaw Buy $34
Oct-08-24Initiated Morgan Stanley Overweight $40
Oct-08-24Initiated Jefferies Buy $35
Oct-08-24Initiated Guggenheim Buy $45
Oct-08-24Initiated Citigroup Buy $27
Mar-16-26 06:01PM
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
07:00AM
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
(GlobeNewswire)
Feb-28-26 10:56AM
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory
(Insider Monkey)
Feb-20-26 04:15PM
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-19-26 07:09AM
Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4
(Insider Monkey)
04:07AM Loading…
Feb-16-26 04:07AM
Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit
(MarketBeat)
Feb-09-26 07:05AM
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
(GlobeNewswire)
Feb-04-26 07:05AM
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
(GlobeNewswire)
Jan-16-26 04:15PM
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-10-26 09:01AM
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
(Benzinga)
Jan-07-26 06:46AM
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes
(Benzinga) +8.62%
Jan-06-26 11:18AM
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
(Zacks) -8.49%
06:25AM
Zenas stock drops 51% despite lead assets Phase III rare disease win
(Clinical Trials Arena)
Jan-05-26 04:23PM
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.
(Investor's Business Daily) -51.86%
07:05AM
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
(GlobeNewswire)
06:26AM Loading…
06:26AM
Zenas shares crash after top drug misses expectations in immune disease study
(BioPharma Dive)
Dec-19-25 04:15PM
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +17.10%
Dec-15-25 07:05AM
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
(GlobeNewswire) -19.71%
Dec-12-25 09:45AM
Huge Insider Buying in MGM and Salesforce
(24/7 Wall St.)
Dec-03-25 07:25AM
Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation
(Insider Monkey) +6.29%
Nov-12-25 07:05AM
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
(GlobeNewswire)
Nov-11-25 07:05AM
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
(GlobeNewswire) +8.41%
Oct-31-25 12:41PM
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
(MarketBeat)
Oct-28-25 01:34PM
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data
(MarketBeat) -5.06%
08:35AM
Zenas bifunctional mAb scores at Phase II in relapsing MS
(Clinical Trials Arena)
06:00AM
Incyte trims pipeline; Zenas surges on MS drug results
(BioPharma Dive)
Oct-27-25 07:05AM
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
(GlobeNewswire) +33.08%
Oct-08-25 05:00AM
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
(GlobeNewswire) +24.22%
Sep-02-25 07:05AM
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
(GlobeNewswire) +9.50%
Aug-26-25 07:05AM
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
(GlobeNewswire)
07:05AM Loading…
Aug-12-25 07:05AM
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
(GlobeNewswire) +6.68%
Jun-20-25 04:15PM
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-13-25 05:45AM
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
(PR Newswire) -8.75%
Jun-02-25 04:00AM
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
(PR Newswire) +5.67%
May-29-25 07:05AM
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire) +8.34%
May-28-25 09:31AM
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
(PR Newswire) -12.59%
May-16-25 05:45AM
Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
(PR Newswire) +7.49%
May-15-25 07:05AM
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
(GlobeNewswire) +12.21%
May-06-25 05:45AM
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
(PR Newswire) -19.71%
May-02-25 05:45AM
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
(PR Newswire)
Apr-29-25 05:45AM
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
(PR Newswire) +12.56%
Apr-22-25 10:37AM
Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses
(GlobeNewswire)
Apr-21-25 12:33PM
Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses
(GlobeNewswire) +9.30%
Apr-17-25 04:20PM
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +7.08%
Apr-07-25 03:08PM
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst
(Seeking Alpha)
07:05AM
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
(GlobeNewswire)
Mar-20-25 02:54PM
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
(Benzinga)
11:41AM
Zenas Bio rises as Wedbush launches with Outperform on lead asset
(SeekingAlpha)
Mar-17-25 07:05AM
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
(GlobeNewswire)
Feb-05-25 07:05AM
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
(GlobeNewswire)
Jan-28-25 08:00AM
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
(GlobeNewswire)
Dec-17-24 06:25AM
Zenas BioPharma initiated with a Buy at H.C. Wainwright
(TipRanks) +8.10%
Dec-12-24 07:35AM
Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley
(TipRanks)
Nov-12-24 07:10AM
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
(GlobeNewswire)
07:05AM
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
(GlobeNewswire)
Nov-07-24 07:05AM
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
(GlobeNewswire)
Oct-14-24 06:45AM
Opening Day: Another trio of biotech IPOs make Friday debut
(TipRanks) +7.63%
Sep-19-24 04:15PM
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
(GlobeNewswire) +8.45%
Sep-13-24 04:09PM
Biotech IPO Shares Climb in Debuts After Deals Upsized
(Bloomberg)
12:19AM
Bicara Leads Trio of US Biotech IPOs Raising $703 Million
(Bloomberg)
Sep-12-24 10:37PM
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
(GlobeNewswire)
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lu HongboDirectorFeb 11 '26Buy22.5025,985584,662347,968Feb 13 05:35 PM
Allen Patricia LDirectorFeb 12 '26Buy24.8515,700390,08815,700Feb 13 05:06 PM
Allen Patricia LDirectorFeb 13 '26Buy26.364,160109,65819,860Feb 13 05:06 PM
MOULDER LEON O JRChief Executive OfficerFeb 02 '26Buy17.9657,0001,023,720423,155Feb 03 04:30 PM
MOULDER LEON O JRChief Executive OfficerJan 07 '26Buy16.3850,000819,000316,155Jan 09 09:42 PM
MOULDER LEON O JRChief Executive OfficerJan 08 '26Buy16.3030,000489,000346,155Jan 09 09:42 PM
MOULDER LEON O JRChief Executive OfficerJan 09 '26Buy16.5520,000331,000366,155Jan 09 09:42 PM
Nunn Jason RaleighDirectorOct 09 '25Buy19.0063,1581,200,0021,173,395Oct 14 05:16 PM
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerOct 09 '25Buy19.00126,3152,399,9851,917,895Oct 14 05:14 PM
ENRIGHT PATRICK GDirectorOct 09 '25Buy19.00105,2652,000,0351,832,669Oct 14 08:59 AM
ENRIGHT PATRICK GDirectorOct 09 '25Buy20.8511,990249,99211,990Oct 14 08:59 AM
MOULDER LEON O JRSee RemarksOct 07 '25Buy20.8536,928769,94936,928Oct 09 05:24 PM
Fairmount Funds Management LLCDirectorOct 07 '25Buy19.00316,2196,008,1612,209,025Oct 09 04:15 PM
Lu HongboDirectorOct 07 '25Buy19.00263,1605,000,040321,983Oct 09 03:37 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

TERN

Terns Pharmaceuticals Inc

Last Close
Mar 24  •  03:54PM ET
49.91
Dollar change
+0.30
Percentage change
0.61 %
Healthcare • Biotechnology • USA • NASD
TERN Terns Pharmaceuticals Inc daily Stock Chart
Peers: MDGL VKTX AKRO MNOV LGND GLMD BCRX XBIT ACAD AMRN
 | Held by: VTI IWM IWN VXF IBB SCHA VTWO IWC IHE DFMC
IndexRUT P/E- EPS (ttm)-1.03 Insider Own9.95% Shs Outstand106.33M Perf Week7.41%
Market Cap5.31B Forward P/E- EPS next Y-1.18 Insider Trans-1.82% Shs Float95.75M Perf Month22.16%
Enterprise Value5.01B PEG- EPS next Q-0.29 Inst Own108.87% Short Float17.35% Perf Quarter25.10%
Income-94.44M P/S- EPS this Y4.83% Inst Trans44.03% Short Ratio7.59 Perf Half Y561.99%
Sales0.00M P/B15.38 EPS next Y-10.70% ROA-27.78% Short Interest16.62M Perf YTD23.55%
Book/sh3.25 P/C17.95 EPS next 5Y-8.32% ROE-29.12% 52W High50.89 -1.92% Perf Year1322.05%
Cash/sh2.78 P/FCF- EPS past 3/5Y17.43% 16.38% ROIC-33.18% 52W Low1.87 2576.36% Perf 3Y459.58%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.54% 5.85% Perf 5Y135.78%
Dividend TTM- EV/Sales- EPS Y/Y TTM12.45% Oper. Margin- ATR (14)2.53 Perf 10Y-
Dividend Ex-Date- Quick Ratio19.52 Sales Y/Y TTM- Profit Margin- RSI (14)72.42 Recom1.09
Dividend Gr. 3/5Y- - Current Ratio19.52 EPS Q/Q4.75% SMA2010.95% Beta-0.33 Target Price58.11
Payout- Debt/Eq0.00 Sales Q/Q- SMA5024.16% Rel Volume0.85 Prev Close49.61
Employees59 LT Debt/Eq0.00 EarningsNov 10 AMC SMA200138.21% Avg Volume2.19M Price49.91
IPOFeb 05, 2021 Option/ShortYes / Yes EPS/Sales Surpr.8.26% - Trades Volume1,832,645 Change0.61%
Date Action Analyst Rating Change Price Target Change
Feb-09-26Initiated Leerink Partners Outperform $58
Nov-04-25Upgrade H.C. Wainwright Neutral → Buy $20
Nov-03-25Upgrade William Blair Mkt Perform → Outperform
Oct-15-25Initiated Truist Buy $20
Sep-17-25Initiated Barclays Overweight $15
Sep-04-25Resumed H.C. Wainwright Neutral
Feb-28-25Initiated William Blair Mkt Perform
Oct-31-24Initiated Oppenheimer Outperform $82
Jun-22-23Initiated Mizuho Buy $16
Jun-07-23Initiated Jefferies Buy $18
Show Previous Ratings
Feb-27-26 04:04PM
Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug
(Insider Monkey)
Feb-25-26 04:05PM
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
(GlobeNewswire)
Feb-23-26 09:06AM
Viatris Stock to Report Q4 Earnings: What's in the Cards?
(Zacks)
Feb-04-26 09:55AM
Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High?
(Zacks) -6.39%
Feb-02-26 04:05PM
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire) +6.42%
04:16AM Loading…
04:16AM
Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment
(Insider Monkey)
Jan-23-26 05:27AM
Novo climbs higher on strong Wegovy pill launch; Terns tweaks leukemia drug deal
(BioPharma Dive)
Jan-15-26 11:35AM
Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN)
(Insider Monkey)
Jan-11-26 01:00AM
Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN)
(Insider Monkey)
Jan-07-26 04:05PM
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) -5.58%
Jan-02-26 04:05PM
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
Dec-19-25 03:14PM
Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders
(Insider Monkey)
Dec-15-25 06:47PM
Terns CEO Amy Burroughs talks cancer drug trial win
(CNBC TV)
Dec-14-25 02:40PM
Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial
(Insider Monkey)
Dec-11-25 04:05PM
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
(GlobeNewswire) +5.56%
11:30PM Loading…
Dec-09-25 11:30PM
Terns Announces Pricing of Upsized $650 Million Public Offering
(GlobeNewswire) +5.82%
03:31PM
Cancer Study Buoys These Small Biotechs
(Barrons.com)
02:23PM
Terns (TERN) Hits All-Time High on Stellar Leukemia Treatment Results
(Insider Monkey)
06:12AM
Terns Announces Proposed Public Offering
(GlobeNewswire)
Dec-08-25 02:45PM
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
(GlobeNewswire) +37.02%
Dec-04-25 07:57AM
These stocks are new additions to Mizuhos Americas Top Picks list
(Investing.com)
Nov-23-25 07:02AM
BMO Believes Market Undervalues Terns Pharmaceuticals (TERN) Despite Strong Trial Data
(Insider Monkey)
Nov-18-25 12:43AM
Terns Pharmaceuticals (TERN) Soars to New Record High of $26.12
(Insider Monkey) +7.82%
Nov-17-25 12:15PM
William Blair Reiterates a Buy on Terns Pharmaceuticals (TERN)
(Insider Monkey) +13.30%
Nov-14-25 04:05PM
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
(GlobeNewswire) +8.83%
Nov-10-25 04:05PM
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
(GlobeNewswire) +7.64%
Nov-04-25 04:05PM
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire) +24.23%
Nov-03-25 09:05AM
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
(GlobeNewswire) +69.85%
Oct-24-25 04:58AM
Chugai buys a kidney biotech; ICER targets rising launch prices
(BioPharma Dive)
Oct-21-25 04:05PM
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
(GlobeNewswire) -5.80%
04:05PM Loading…
Oct-02-25 04:05PM
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
Sep-21-25 10:45AM
2 Under-the-Radar Stocks That Could Soar
(Motley Fool)
Aug-21-25 04:05PM
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
(GlobeNewswire) +7.30%
Aug-07-25 09:55AM
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
(Benzinga)
Aug-05-25 04:05PM
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
(GlobeNewswire) +5.74% -6.74%
Aug-04-25 04:05PM
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire) +5.12%
Jun-23-25 04:07PM
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
(GlobeNewswire) -5.64%
May-29-25 04:05PM
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
(GlobeNewswire)
May-14-25 09:30AM
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
(GlobeNewswire)
May-09-25 07:54AM
Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?
(Insider Monkey)
May-08-25 04:05PM
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
(GlobeNewswire)
May-02-25 04:05PM
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire) -5.71%
Apr-30-25 04:05PM
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
(GlobeNewswire) +6.11% +7.88%
Apr-26-25 08:50AM
Novo Nordisk: Examining Tariff And Pricing Risks
(Seeking Alpha)
Apr-07-25 09:35AM
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
(Zacks)
Apr-03-25 09:35AM
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
(Zacks) -6.43%
Apr-02-25 04:05PM
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
Mar-26-25 12:00PM
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
(Zacks) -6.63%
Mar-20-25 04:05PM
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
(GlobeNewswire) +6.69%
Mar-09-25 10:03AM
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
(Motley Fool)
Feb-26-25 04:05PM
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
Feb-25-25 08:05AM
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
(GlobeNewswire)
03:00AM
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
(Pharma Voice)
Feb-24-25 04:05PM
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
(GlobeNewswire) -6.87%
Feb-20-25 04:05PM
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
(GlobeNewswire)
Feb-05-25 04:05PM
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
Feb-03-25 04:05PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
Jan-08-25 04:05PM
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) -6.84%
Jan-02-25 04:05PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
Dec-16-24 01:10PM
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
(Insider Monkey)
Dec-03-24 07:00AM
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
(GlobeNewswire)
Dec-02-24 04:05PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
Nov-18-24 04:05PM
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
(GlobeNewswire) -7.62%
Nov-12-24 04:05PM
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
(GlobeNewswire) -5.44%
Nov-06-24 04:05PM
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
(GlobeNewswire)
Oct-07-24 04:05PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire) -5.08%
Sep-24-24 03:22AM
Insiders Snap Up These 2 Strong Buy Stocks
(TipRanks)
Sep-18-24 10:07AM
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
(Motley Fool) +6.02%
Sep-17-24 01:30AM
OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc
(GuruFocus.com)
Sep-15-24 07:21AM
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
(Motley Fool)
06:09AM
Should You Invest in This Under-the-Radar Weight Loss Stock?
(Motley Fool)
Sep-14-24 10:12AM
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More
(Motley Fool)
Sep-12-24 07:00PM
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
(GlobeNewswire) -10.96% -5.84%
Sep-10-24 10:50PM
Terns Announces Pricing of Upsized $150.15 Million Public Offering
(GlobeNewswire) +23.14%
04:52AM
Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment
(Clinical Trials Arena)
Sep-09-24 04:01PM
Terns Announces Proposed Public Offering
(GlobeNewswire) +16.77%
09:58AM
Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill
(Barrons.com)
09:24AM
Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month
(Benzinga)
08:06AM
Early study data puts Terns among obesity drug contenders
(BioPharma Dive)
07:05AM
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
(GlobeNewswire)
Aug-28-24 09:55AM
Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet
(Zacks)
Aug-05-24 09:56PM
TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024
(InvestorPlace)
04:05PM
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
(GlobeNewswire)
Aug-02-24 01:54PM
3 Biotech Stocks That Could Have Investors Grinning Soon
(InvestorPlace)
Aug-01-24 04:05PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
Jul-29-24 04:05PM
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
(GlobeNewswire) -7.55% -7.92%
Jul-26-24 06:40PM
Burger King Parent Company and More Stocks See Action From Activist Investors
(Barrons.com)
Jul-20-24 09:30AM
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
(Motley Fool)
Jun-21-24 06:30PM
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation
(GlobeNewswire)
Jun-19-24 01:27PM
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
(Zacks)
Jun-04-24 09:55AM
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade
(Zacks)
Jun-03-24 04:10PM
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire)
May-30-24 08:05AM
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
(GlobeNewswire)
May-17-24 04:05PM
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
(GlobeNewswire) +5.93%
May-13-24 01:53PM
TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024
(InvestorPlace) +5.94%
09:32AM
Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections
(GuruFocus.com)
08:05AM
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
(GlobeNewswire)
May-08-24 04:05PM
Terns Pharmaceuticals Announces Leadership Changes
(GlobeNewswire) +5.03%
May-07-24 04:05PM
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
(GlobeNewswire)
May-03-24 04:05PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
(GlobeNewswire) +6.43%
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burroughs Amy L.Chief Executive OfficerMar 16 '26Option Exercise4.6414,58367,665303,559Mar 17 06:10 PM
Burroughs Amy L.Chief Executive OfficerMar 16 '26Sale46.7114,583681,108288,976Mar 17 06:10 PM
Burroughs Amy L.Chief Executive OfficerFeb 17 '26Option Exercise4.6414,58367,665303,559Feb 18 07:01 PM
Burroughs Amy L.Chief Executive OfficerFeb 17 '26Sale39.1914,583571,579288,976Feb 18 07:01 PM
Burroughs Amy L.Chief Executive OfficerJan 15 '26Option Exercise4.6468,749318,995357,725Jan 16 05:22 PM
Burroughs Amy L.Chief Executive OfficerJan 15 '26Sale37.0768,7492,548,603288,976Jan 16 05:22 PM
AMY BURROUGHSDirectorJan 15 '26Proposed Sale37.1897,9153,640,480Jan 15 04:24 PM
Burroughs Amy L.Chief Executive OfficerJan 02 '26Option Exercise4.6421,55199,99760,315Jan 06 08:26 PM
Burroughs Amy L.Chief Executive OfficerJan 05 '26Sale38.1071,3392,718,230138,976Jan 06 08:26 PM
Kuriakose EmilChief Medical OfficerJan 02 '26Sale38.571,15544,55250,365Jan 06 08:25 PM
Quigley Jill M.DirectorNov 04 '25Option Exercise9.2424,520226,56524,520Nov 05 06:17 PM
Quigley Jill M.DirectorNov 04 '25Sale18.0024,520441,3600Nov 05 06:17 PM
JILL QUIGLEYDirectorNov 04 '25Proposed Sale14.0324,520344,016Nov 04 04:32 PM
Kuriakose EmilChief Medical OfficerOct 01 '25Sale7.859447,40751,520Oct 02 07:24 PM
Kuriakose EmilChief Medical OfficerJul 01 '25Sale4.278533,64052,464Jul 03 02:55 PM
Gengos AndrewChief Financial OfficerJun 27 '25Buy3.9310,00039,28325,000Jun 30 05:38 PM
Burroughs Amy L.Chief Executive OfficerJun 25 '25Buy3.8723,31490,23047,083Jun 25 06:08 PM
Gengos AndrewChief Financial OfficerJun 13 '25Buy3.7310,00037,35010,000Jun 16 06:05 PM
Gengos AndrewChief Financial OfficerJun 16 '25Buy3.955,00019,73215,000Jun 16 06:05 PM
Kuriakose EmilChief Medical OfficerApr 01 '25Sale2.499522,36653,317Apr 02 06:48 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)